These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 14764025)
1. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology. Kim EE Int J Gynecol Cancer; 2004; 14(1):12-22. PubMed ID: 14764025 [TBL] [Abstract][Full Text] [Related]
2. Comparing 18-fluoro-2-deoxyglucose positron emission tomography with a combination of technetium 99m tetrofosmin single photon emission computed tomography and computed tomography to detect recurrent or persistent nasopharyngeal carcinomas after radiotherapy. Kao CH; Tsai SC; Wang JJ; Ho YJ; Yen RF; Ho ST Cancer; 2001 Jul; 92(2):434-9. PubMed ID: 11466699 [TBL] [Abstract][Full Text] [Related]
3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344 [TBL] [Abstract][Full Text] [Related]
4. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206 [TBL] [Abstract][Full Text] [Related]
5. PET and PET-CT for evaluation of colorectal carcinoma. Delbeke D; Martin WH Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102 [TBL] [Abstract][Full Text] [Related]
6. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Kao CH; Shiau YC; Shen YY; Yen RF Cancer; 2002 Apr; 94(7):1981-6. PubMed ID: 11932900 [TBL] [Abstract][Full Text] [Related]
8. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088 [TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography scanning in gynecologic and breast cancers. Zimny M; Siggelkow W Curr Opin Obstet Gynecol; 2003 Feb; 15(1):69-75. PubMed ID: 12544505 [TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554 [TBL] [Abstract][Full Text] [Related]
11. Whole-body Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514 [TBL] [Abstract][Full Text] [Related]
12. Differentiating recurrent or residual nasopharyngeal carcinomas from post-radiotherapy changes with 18-fluoro-2-deoxyglucose positron emission tomography and thallium-201 single photon emission computed tomography in patients with indeterminate computed tomography findings. Tsai MH; Huang WS; Tsai JJ; Chen YK; Changlai SP; Kao CH Anticancer Res; 2003; 23(4):3513-6. PubMed ID: 12926100 [TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949 [TBL] [Abstract][Full Text] [Related]
15. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Salem SS; Shahin MA Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387 [TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: diagnostic accuracy and impact on clinical management. Gordin A; Golz A; Daitzchman M; Keidar Z; Bar-Shalom R; Kuten A; Israel O Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):370-6. PubMed ID: 17324532 [TBL] [Abstract][Full Text] [Related]
17. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387 [TBL] [Abstract][Full Text] [Related]
18. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584 [TBL] [Abstract][Full Text] [Related]
19. PET/Computed Tomography in the Diagnosis and Staging of Gastric Cancers. Malibari N; Hickeson M; Lisbona R PET Clin; 2015 Jul; 10(3):311-26. PubMed ID: 26099669 [TBL] [Abstract][Full Text] [Related]
20. Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. De Gaetano AM; Calcagni ML; Rufini V; Valentini AL; Gui B; Giordano A; Bonomo L Abdom Imaging; 2009 Nov; 34(6):696-711. PubMed ID: 18791682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]